Integrative Bioinformatics Analysis of Liver Transcriptomics and Serum Fibroblast Growth Factor 21 Protein Levels in Monitoring Progressive Fibrotic Liver Disease
Mathematical Biology and Bioinformatics · 29.04.2026 · 21 (1) · 175-186
DOI: 10.17537/2026.21.175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mathematical Biology and Bioinformatics, online erschienen am 29.04.2026. Verfasst von Hawraa M. Alaa Alden und 3 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Advanced fibrosis defines mortality risk in chronic liver disease. Current diagnostics fail to capture the molecular transition from early injury to permanent scarring. They often rely on binary classifications obscuring the biological drivers of disease progression. We mapped the gene expression profiles differentiating advanced (F3-F4) from early (F0-F2) fibrosis to determine their cellular origin and protein-level translatability across distinct disease etiologies. We analyzed public bulk RNA-sequencing data (E-MTAB-6863) to isolate genes distinguishing early from advanced fibrosis. We then deconvoluted these signals using single-nucleus RNA-sequencing (snRNA-seq; GSE179548) to identify specific cell types. We validated candidates proteomically in a multi-omics hepatocellular carcinoma dataset comparing viral versus metabolic etiologies. We identified a 105-gene signature associated with advanced fibrosis enriched for extracellular matrix organization and epithelial development. snRNA-seq localized this signal primarily to cholangiocytes rather than hepatic stellate cells indicating a ductular reaction. Proteomic validation showed a divergence. Structural markers (COL1A1, THY1) remained elevated regardless of etiology. Metabolic and ductular markers (AKR1B10, KRT23, SPP1) were specific to metabolic conditions (NAFLD alcoholic liver disease). Advanced fibrosis is fueled by a biliary epithelial response not just matrix deposition. The fibrotic scaffold is conserved across patients. The accompanying metabolic adaptations are etiology dependent. This suggests that effective biomarkers must be tailored to the specific metabolic context of the disease rather than relying on a universal fibrosis panel.
Zitieren
APA
Alden, H. M. A., Ali, H. R., Lazim, A. J., & Suleiman, A. A. (2026). Integrative Bioinformatics Analysis of Liver Transcriptomics and Serum Fibroblast Growth Factor 21 Protein Levels in Monitoring Progressive Fibrotic Liver Disease. Mathematical Biology and Bioinformatics, 21(1), 175-186. https://doi.org/10.17537/2026.21.175
Vancouver
Alden HMA, Ali HR, Lazim AJ, Suleiman AA. Integrative Bioinformatics Analysis of Liver Transcriptomics and Serum Fibroblast Growth Factor 21 Protein Levels in Monitoring Progressive Fibrotic Liver Disease. Mathematical Biology and Bioinformatics. 2026;21(1):175-186. doi:10.17537/2026.21.175
BibTeX
@article{Alden2026,
author = {Alden, Hawraa M. Alaa and Ali, Haneen Rafea and Lazim, Afrah Jabbar and Suleiman, Ahmed AbdulJabbar},
title = {Integrative Bioinformatics Analysis of Liver Transcriptomics and Serum Fibroblast Growth Factor 21 Protein Levels in Monitoring Progressive Fibrotic Liver Disease},
journal = {Mathematical Biology and Bioinformatics},
year = {2026},
volume = {21},
number = {1},
pages = {175--186},
doi = {10.17537/2026.21.175}
}
EUVIMED